布罗达卢马布治疗中度至重度的性腺炎:在实际临床实践中进行的一项开放式多中心队列研究
Guiovana Fernanda Osorio-Gómez1, Juan Ortiz-Álvarez1, Delia Diaz-Ceca2
1Dermatology Unit, Hospital Universitario Virgen del Rocío, Seville, Spain.
The Australasian journal of dermatology
|April 10, 2024
概括
布罗达卢马布在治疗中度至重度的补性腺炎 (HS) 方面表现有前途. 这种生物疗法有效地减少了50%的患者的疾病严重程度,为HS管理提供了新的选择.
科学领域:
- 免疫皮肤学 免疫皮肤学
- 生物疗法 生物疗法
- 炎症性皮肤疾病是一种炎症性皮肤疾病.
背景情况:
- 补腺炎 (HS) 的发病包括免疫失调,TNF-alfa和IL-17的水平升高.
- 生物疗法越来越多地用于HS管理.
- 布罗达卢马布向IL-17受体A,表明HS的潜在治疗疗效.
研究的目的:
- 评估布罗达卢马布在中度至重度腹炎 (HS) 患者的疗效和安全性.
- 为了评估治疗反应,使用Hidradenitis Suppurativa临床反应 (HiSCR) 和IHS4评分.
主要方法:
- 一项多中心,回顾性,开放性研究包括16名中度至重度HS的成年人,他们接受了210毫克的布罗达卢马布治疗.
- 患者在基线和第16周 (中位随访) 被评估.
- 分析了人口,疾病,反应 (HiSCR,IHS4) 和安全数据.
主要成果:
- 50%的患者实现了HiSCR,平均IHS4得分从24.13显著下降到16.81 (p=0.002).
- 在达到HiSCR的患者和没有达到HiSCR的患者之间没有观察到显著差异.
- 三名患者发生了2级不良事件;四名患者停止治疗.
结论:
- 布罗达卢马布在中度至重度的HS患者中显示出有效性和良好的安全性.
- 它可能是一个可行的治疗选择,耐药的患者,以阿达利姆巴.
- 布罗达卢马布代表了一种有前途的治疗替代方案,用于补性炎.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:29Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
01:17Drugs for Treatment of Diarrhea-Predominant IBS
163
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
163